ライフサイエンスコーパス: podocalyxin

1 action (e.g., angiotensin converting enzyme, podocalyxin).

2 invasiveness in cancer cells overexpressing podocalyxin.

3 lylation of the major podocyte sialoprotein, podocalyxin.

4 gulation of synaptopodin, WT-1, nephrin, and podocalyxin.

5 te differentiation markers, synaptopodin and podocalyxin.

6 ll adhesion molecule 1 (GlyCAM-1), CD34, and podocalyxin.

7 nt the human homolog of rabbit PCLP1 and rat podocalyxin.

8 at) and recognized both rabbit PCLP1 and rat podocalyxin.

9 lated previously and confirmed recently that podocalyxin, a sialomucin, plays a major role in maintai

10 Overexpression of podocalyxin also affected transepithelial resistance and

11 her the highly conserved cytoplasmic tail of podocalyxin also contributes to the unique organization

12 n to its ectodomain, the cytoplasmic tail of podocalyxin also likely contributes to maintaining the u

13 To assess its function, we cloned rat podocalyxin and examined the effects of its expression o

14 on of the genes for NPHS1, NPHS2, CD2AP, and podocalyxin and may involve other genes yet to be implic

15 Podocytes in ectatic tubules expressed podocalyxin and podocin proteins but not nephrin, compat

16 By immunocytochemistry, it was shown that podocalyxin and the actin binding protein ezrin are co-e

17 n alpha3beta1 expression, as well as that of podocalyxin and the slit diaphragm component ZO-1.

18 Thus, CD34, podocalyxin, and endoglycan comprise a family of sialomu

19 ed renal histology, increased sialylation of podocalyxin, and increased Gne/Mnk protein expression an

20 ncluding WT-1, CALLA, C3b receptor, GLEPP-1, podocalyxin, and synaptopodin.

21 CD34 and podocalyxin are structurally related sialomucins, which

22 ed glomerular expression of both nephrin and podocalyxin as well as enhanced susceptibility to glomer

23 ith improved sialylation of both nephrin and podocalyxin, as well as reduced albuminuria compared wit

24 switch mechanism results in the retention of Podocalyxin at the ECM interface and the development ins

25 eatment with PAN increased the expression of podocalyxin at the protein and mRNA levels.

26 e two other members of this family (CD34 and podocalyxin) can function as a L-selectin ligand.

27 CRISPR/Cas9 knockout of podocalyxin causes junctional organization defects in po

28 y, membrane translocation, and reassembly of podocalyxin complexes controls epithelial cell polarizat

29 Endoglycan (EG) together with CD34 and podocalyxin comprise the CD34 family of sialomucins.

30 ial centrifugation revealed that some of the podocalyxin cosediments with actin filaments.

31 To determine the role of ezrin in these podocalyxin-dependent phenotypic events, we first confir

32 Podocalyxin expression also led to an increase in mitoge

33 ng differentiation-dependent upregulation of podocalyxin expression BASP1 occupancy of the podocalyxi

34 Once formed, podocalyxin/ezrin complexes are very stable, because the

35 t phenotypic events, we first confirmed that podocalyxin formed a complex with ezrin in MCF7 and PC3

36 g Podocalyxin/NHERF1/Ezrin complex, removing Podocalyxin from the ECM-abutting cell surface and initi

37 These results provide direct evidence that podocalyxin functions as an antiadhesin that maintains a

38 ding of WT1 to conserved elements within the Podocalyxin gene promoter results in potent transcriptio

39 1 occupy the promoters of the Bak, c-myc and podocalyxin genes in podocyte precursor cells.

40 ns concentrate in the cilium, others such as podocalyxin/gp135 are excluded.

41 Here, we show that overexpression of podocalyxin in MCF7 breast cancer and PC3 prostate cance

42 tion, and the specific expression pattern of Podocalyxin in the developing kidney mirrors that of WT1

43 ic acid prevented sialylation of nephrin and podocalyxin in the maturing podocyte where it is require

44 The mechanism through which podocalyxin increases cancer aggressiveness remains poor

45 In EcR-CHO cells, the expression level of podocalyxin induced by increasing levels of ecdysone ana

46 Podocalyxin is a major membrane protein of the glomerula

47 Podocalyxin is a type 1 transmembrane sialoprotein with

48 Podocalyxin is an anti-adhesive transmembrane sialomucin

49 These data indicate that in podocytes, podocalyxin is complexed with ezrin, which mediates its

50 ssion of the nonciliary apical protein gp135/podocalyxin is greatly decreased.

51 Podocalyxin is immobilized by its PDZ interaction motif

52 These findings suggest that podocalyxin leads to increased in vitro migration and in

53 n factor-3 (Gdf3), oncostatin-M (OncoM), and podocalyxin like-1 (PODXL).

54 noncanonical EPO/EPOR response factors (e.g. podocalyxin like-1, tribbles 3, reactive oxygen species,

55 est region of allelic imbalance contains the podocalyxin-like (PODXL) gene, which we evaluate here as

56 Podocalyxin-like protein (PCLP) is a transmembrane sialo

57 teins, CD44, carcinoembryonic antigen (CEA), podocalyxin-like protein (PCLP), and melanoma cell adhes

58 ectively expressed in the early progenitors: podocalyxin-like protein (PODXL), alpha6-integrin (CD49f

59 r identified the embryonal carcinoma antigen podocalyxin-like protein 1 (PODXL), an anti-adhesive pro

60 qQ > L, there was a significant reduction in podocalyxin mRNA as well as nephrin mRNA and protein lev

61 phosphorylates the apical identity-promoting Podocalyxin/NHERF1/Ezrin complex, removing Podocalyxin f

62 Podocalyxin (PC) is the major sialoglycoprotein expresse

63 Podocalyxin (PC), the major sialoprotein of glomerular e

64 on, as seen by failed localization of apical podocalyxin (PODXL) and basal actin.

65 53-mediated repression in this system is the podocalyxin (PODXL) gene.

66 in primordial follicle formation, including podocalyxin (Podxl), PDGFR-beta, and a follistatin-domai

67 Most L-selectin ligands such as CD34 and podocalyxin present sulfated carbohydrate structures (6-

68 odocalyxin expression BASP1 occupancy of the podocalyxin promoter is reduced compared to that of WT1.

69 d have additive or repressive effects on the Podocalyxin promoter, depending on dosage.

70 il now there has been no direct evidence for podocalyxin's function.

71 ssay, CHO-K1 cells expressing high levels of podocalyxin showed complete inhibition of cell aggregati

72 of c-kit-positive cells expresses Flk-1 and podocalyxin, suggesting that this cell population includ

73 cursors leads to the induction of endogenous Podocalyxin, the major structural membrane protein of gl

74 oJ are required for polarized trafficking of podocalyxin to the early apical surface--an important ev

75 Rabs and Rab effectors are used to regulate podocalyxin trafficking in two- versus three-dimensional

76 1, nephrin, glomerular epithelial protein 1, podocalyxin, vascular endothelial growth factor, and alp

77 Furthermore, expression of podocalyxin was associated with a changed ezrin subcellu

78 Podocalyxin was downregulated by 20% in newborn kidneys

79 The inhibitory effect of podocalyxin was reversed by treatment of the cells with

80 The glomerular glycoproteins nephrin and podocalyxin were hyposialylated in this unique murine mo

81 nderstood but may involve the interaction of podocalyxin with ezrin, an established mediator of metas

82 cell polarity requires apical trafficking of podocalyxin; yet the regulation of its transport is uncl